Zacks Initiates Coverage of SLSN With Underperform Recommendation

Discover why Zacks issues an "Underperform" rating for Solesence, being the first on Wall Street to initiate coverage on the stock. Learn how margin pressure, cash flow weakness, rising leverage and execution challenges are weighing on growth.